Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Investing Activities (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Cash from Investing Activities for 4 consecutive years, with $61.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 37.77% to $61.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$175.4 million, a 1360.67% decrease, with the full-year FY2024 number at $31.3 million, up 124.62% from a year prior.
  • Cash from Investing Activities was $61.9 million for Q3 2025 at Centessa Pharmaceuticals, up from -$40.0 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $61.9 million in Q3 2025 to a low of -$222.4 million in Q1 2025.
  • A 4-year average of -$19.8 million and a median of -$240000.0 in 2022 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 304512.5% in 2023; the steepest drop was 35873.33% in 2023.
  • Centessa Pharmaceuticals' Cash from Investing Activities stood at -$446000.0 in 2022, then tumbled by 3997.53% to -$18.3 million in 2023, then surged by 236.8% to $25.0 million in 2024, then skyrocketed by 147.78% to $61.9 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Cash from Investing Activities are $61.9 million (Q3 2025), -$40.0 million (Q2 2025), and -$222.4 million (Q1 2025).